Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
Cingulate Inc (CING) Stock Price & Analysis
99 Followers
CING Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $21.80
Previous Close$0.79
Volume65.09K
Average Volume (3M)175.34K
Market Cap
$3.15M
Enterprise Value$4.76M
Total Cash (Recent Filing)$1.99M
Total Debt (Recent Filing)$3.60M
Price to Earnings (P/E)>-0.1
Beta-0.85
Next Earnings
Aug 12, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.91
Shares Outstanding6,046,479
10 Day Avg. Volume100,791
30 Day Avg. Volume175,341
Standard Deviation0.33
R-Squared0.02
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-47.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Cingulate Inc News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentCTx-1301 has shown a rapid onset and effect sizes greater than most marketed therapies, indicating strong potential if it reaches the market.
Financial PerformanceOperating expenses were significantly lower than expected due to reduced R&D and SG&A, suggesting improved cost management.
Product InnovationCingulate’s Precision Timed Release (PTR) drug delivery technology can deliver once-daily oral therapies that provide all day efficacy while eliminating the need for boosters.
Bears Say
Capital Raise ConcernsAdditional funding will be necessary by the end of 2Q24 and might be significantly dilutive, which casts uncertainty on the stock's outlook.
Clinical TrialsClinical trials for CTx-1301 were paused due to financial constraints, and the company is still evaluating how to proceed.
Financial HealthCingulate reported a net loss and ended the period with limited cash, implying additional capital will likely be required soon.
---
Ownership Overview
66.85% Insiders
0.24% Mutual Funds
2.58% Other Institutional Investors
30.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $0.70 and its highest was $21.80 in the past 12 months.
What is Cingulate Inc’s market cap?
Currently, no data Available
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 12, 2024 which is in 89 days.
How were Cingulate Inc’s earnings last quarter?
Currently, no data Available
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Overvalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -$0.47.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,977,171 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 1K.
---
Cingulate Inc Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $1.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.12%
12-Months-Change
Fundamentals
Return on Equity
-1364.73%
Trailing 12-Months
Asset Growth
-23.29%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
---
CING Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-81.97%
reiterated a buy rating 5 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -81.97% per trade.
---